Business
Marina Biotech to Present New Data for IT-102 and IT-103 at the 7th International Conference on Fixed Combination in Cannes, France
Marina Biotech to Present New Data for IT-102 and IT-103 at the 7th International Conference on Fixed Combination in Cannes, France.
About this update from Adhera Therapeutics Inc.
[{"type":"text","content":"\n \n \n Marina Biotech to Present New Data for IT-102 and IT-103 at the 7th International Conference on Fixed Combination in Cannes, France\n \n \nMarina Biotech to Present New Data for IT-102 and IT-103 at the 7th International Conference on Fixed Combination in Cannes, France\n \n CITY OF INDUSTRY, CA--(Marketwired - Mar 2, 2017) - Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, today announced that new data related to its IT-102 and IT-103 will be presented at the 7th International Conference on Fixed Combination in the Treatment of Hypertension, Dyslipidemia and Diabetes Mellitus in Cannes, France on March 2-5, 2017.\n Dr. Vuong Trieu, Chairman of the Board for Marina Biotech, will present a poster on the clinical development of Celecoxib-Lisinopril FDC (IT-102) and Celecoxib-Olmesartan FDC (IT-103) against combined arthritis/hypertension. This is a retrospective study that uses two patient level data sources over a three year period. These FDCs are being developed as next generation Celecoxib -- Celecoxib without Celecoxib drug-induced edema -- as inhibitor of the beta-catenin/COX-2 axis for the treatment of pain, arthritis, and cancers such as FAP and CRC. \n \n \n On Saturday, March 4, the oral presentation will take place at 12:10 PM in Hall A: \"Rosuvastatin / Olmesartan FDC for the Treatment of CAD, authored by Vuong Trieu, Wen Wang, and Larn Hwang\"\n \n \nOn Sunday, March 5, the poster presentation will take place at 10:00 AM in Hall A: \"Celecoxib FDCs for the treatment of Arthritis, authored by Vuong Trieu, Sanjive Qazi, Lynne Murphy, Anshuma Mehta, Wen Wang, Mihir Munsif, and Zachary Yim\"\n \n \n \"These presentations will unveil how Marina Biotech, together with Autotelic Inc., is leveraging FDCs to treat the often neglected disease intersections, as well as improving already safe drugs for novel indications, especially cancer,\" stated Joseph Ramelli, CEO of Marina Biotech. \n About Marina Biotech\n Marina Biotech is a biotechnology company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension, and cancer. Our pipeline includes combination therapies of oligonucleotide-based the...